Alnylam Pharmaceuticals Inc


Market Cap$20.25B

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Alnylam Pharmaceuticals IncAlnylam Pharmaceuticals Inc-610%151%10.5-4.7

Target Price by Analysts

49% upsideAlnylam Pharmaceuticals Target Price DetailsTarget Price

Current Fair Value

2.1% upside

Undervalued by 2.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$20.25 Billion
Enterprise Value$18.90 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$-2.65
Outstanding Shares126,491,778
Avg 30 Day Volume618,830


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-60.97
Price to Sales10.49
Price to Book Ratio-78.7
Enterprise Value to Revenue9.43
Enterprise Value to EBIT-107.48
Enterprise Value to Net Income-57
Total Debt to Enterprise0.05
Debt to Equity-4.66

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Alnylam Pharmaceuticals Inc

CEO: John Maraganore